Tumor size predicts survival in mucinous gastric carcinoma

Journal of Surgical Oncology

Volumn 106, Issue 6, 2012, Pages 757-764

  Sung, Chang Ohk ^a   Lee, Sun Mi ^b   Choi, Jong Sun ^c   Kim, Kyoung Mee ^a   Choi, Min Gew ^a   Noh, Jae Hyung ^a   Sohn, Tae Sung ^a   Bae, Jae Moon ^a   Kim, Woo Ho ^d   Park, Cheol Keun ^a   Kim, Sung ^a  

^a Sungkyunkwan University   (South Korea)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Dongguk University Ilsan Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

carcinoma; EGFR; gastric; HER2; histology; mucinous; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; FEMALE; GASTRECTOMY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS GASTRIC CARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84867843578     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23141     Document Type: Article

References (25)

1. Hamilton SR, Aaltonen LA:, editors. Pathology and genetics of tumours of the digestive system. Lyon, France: IARC; 2000.
2. Choi MG, Sung CO, Noh JH, et al.: Mucinous gastric cancer presents with more advanced tumor stage and weaker beta-catenin expression than nonmucinous cancer. Ann Surg Oncol 2010; 17: 3053-3058.
3. Adachi Y, Mori M, Kido A, et al.: A clinicopathologic study of mucinous gastric carcinoma. Cancer 1992; 69: 866-871.
4. Kunisaki C, Akiyama H, Nomura M, et al.: Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol 2006; 13: 836-842.
5. Woo LS, Kim DY, Kim YJ, et al.: Clinicopathologic features of mucinous gastric carcinoma. Dig Surg 2002; 19: 286-290.
6. Wu CY, Yeh HZ, Shih RT, et al.: A clinicopathologic study of mucinous gastric carcinoma including multivariate analysis. Cancer 1998; 83: 1312-1318.
7. Yasuda K, Adachi Y, Shiraishi N, et al.: Pathology and prognosis of mucinous gastric carcinoma. J Surg Oncol 2001; 76: 272-277.
8. Choi JS, Kim MA, Lee HE, et al.: Mucinous gastric carcinomas: Clinicopathologic and molecular analyses. Cancer 2009; 115: 3581-3590.
9. Kawamura H, Kondo Y, Osawa S, et al.: A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer 2001; 4: 83-86.
10. Rosenberg J, Chia YL, Plevritis S:, The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat 2005; 89: 47-54.
11. Foulkes WD, Reis-Filho JS, Narod SA:, Tumor size and survival in breast cancer-a reappraisal. Nat Rev Clin Oncol 2010; 7: 348-353.
12. Adachi Y, Oshiro T, Mori M, et al.: Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol 1997; 4: 137-140.
13. Giuliani A, Caporale A, Di Bari M, et al.: Maximum gastric cancer diameter as a prognostic indicator: Univariate and multivariate analysis. J Exp Clin Cancer Res 2003; 22: 531-538.
14. Saito H, Osaki T, Murakami D, et al.: Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg 2006; 192: 296-300.
15. Shiu MH, Perrotti M, Brennan MF:, Adenocarcinoma of the stomach: A multivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterology 1989; 36: 7-12.
16. Wang X, Wan F, Pan J, et al.: Tumor size: A non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol 2008; 97: 236-240.
17. Yokota T, Ishiyama S, Saito T, et al.: Is tumor size a prognostic indicator for gastric carcinoma ? Anticancer Res 2002; 22: 3673-3677.
18. Edge SB, Byrd DR, Compton CC, et al.: editors. " AJCC cancer staging manual," 7th edition. Springer-Verlag; 2009.
19. Hofmann M, Stoss O, Shi D, et al.: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008; 52: 797-805.
20. Kimura M, Tsuda H, Morita D, et al.: A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004; 445: 255-262.
21. Bhargava R, Chen B, Klimstra DS, et al.: Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006; 106: 1857-1862.
22. Song HJ, Srivastava A, Lee J, et al.: Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 2010; 139: 84-92, e82.
23. Kim MA, Lee HS, Lee HE, et al.: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52: 738-746.
24. Gravalos C, Jimeno A:, HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
25. Kim JS, Kim MA, Kim TM, et al.: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: Epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 2009; 100: 732-738.